Deerfield is a founding investor of Neomorph and invested through its Series A Preferred financing. Neomorph’s mission is to build a leading protein degradation company that will advance the science and technology of molecular glue drug discovery, while establishing a sustainable pipeline of projects and progressing these into the clinic. The Company leadership is composed of experts in the field of protein degradation.